Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy
BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia among adults in Western countries; however, it is relatively rare in Asia. It is characterized by abnormal proliferation of lymphocytes in the blood, bone marrow, and lymphatic tissue. The measurement of serum beta-2...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
| Series: | Iraqi Journal of Hematology |
| Subjects: | |
| Online Access: | http://www.ijhonline.org/article.asp?issn=2072-8069;year=2020;volume=9;issue=2;spage=155;epage=159;aulast=Al-Rekabi |
| _version_ | 1818414101753233408 |
|---|---|
| author | Abdulameer Nasser Al-Rekabi Alaa Fadhil Alwan Naseer Khaleel Alobaidi |
| author_facet | Abdulameer Nasser Al-Rekabi Alaa Fadhil Alwan Naseer Khaleel Alobaidi |
| author_sort | Abdulameer Nasser Al-Rekabi |
| collection | DOAJ |
| description | BACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia among adults in Western countries; however, it is relatively rare in Asia. It is characterized by abnormal proliferation of lymphocytes in the blood, bone marrow, and lymphatic tissue. The measurement of serum beta-2 microglobulin (B2M) is essential for baseline workup of multiple myeloma and follicular lymphoma patients. CD49d, an adhesion molecule mediating cell-to-cell and cell-to-extracellular matrix interactions, represents a novel and the most reliable immunophenotypic marker regarding prognosis and independent of other markers.
OBJECTIVES: This study aimed to assess the level of B2M and CD49d in serum CLL patients and correlates them with treatment response.
PATIENTS AND METHODS: this is a prospective cohort study conducted on 70 patients with CLL and 40 healthy people as a control group. Patient groups were divided into two groups: The first group included 38 patients before receiving treatment and the second group included 32 patients posttreatment. Diagnosis was based on lymphocyte count of >5 × 109/L and immunophenotyping. The measurement of level B2M and CD49d in serum patients was done using enzyme-linked immunosorbent assay.
RESULTS: there were 53 males and 17 females, the mean age was 59.12 ± 14.23, and the most clinical presentation was lymphadenopathy. Regarding the mean of B2M, it was 2.19 ± 0.86, 1.86 ± 0.58, and 1.41 ± 0.44 in the pre, post, and control groups, respectively, with P = 0.0001. Regarding the mean of CD49d, it was 0.22 ± 0.15, 0.30 ± 0.44, and 0.19 ± 0.13 in the pre, post, and control groups, respectively, with P = 0.211.
CONCLUSION: this study showed that CD49d has no clinical impact on the treatment outcome, yet B2M has an important prognostic factor in deciding patients in advance stage. |
| first_indexed | 2024-12-14T11:13:45Z |
| format | Article |
| id | doaj.art-50dab341d17042898f8b46dbd53a5e82 |
| institution | Directory Open Access Journal |
| issn | 2072-8069 |
| language | English |
| last_indexed | 2024-12-14T11:13:45Z |
| publishDate | 2020-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Iraqi Journal of Hematology |
| spelling | doaj.art-50dab341d17042898f8b46dbd53a5e822022-12-21T23:04:08ZengWolters Kluwer Medknow PublicationsIraqi Journal of Hematology2072-80692020-01-019215515910.4103/ijh.ijh_44_20Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapyAbdulameer Nasser Al-RekabiAlaa Fadhil AlwanNaseer Khaleel AlobaidiBACKGROUND: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia among adults in Western countries; however, it is relatively rare in Asia. It is characterized by abnormal proliferation of lymphocytes in the blood, bone marrow, and lymphatic tissue. The measurement of serum beta-2 microglobulin (B2M) is essential for baseline workup of multiple myeloma and follicular lymphoma patients. CD49d, an adhesion molecule mediating cell-to-cell and cell-to-extracellular matrix interactions, represents a novel and the most reliable immunophenotypic marker regarding prognosis and independent of other markers. OBJECTIVES: This study aimed to assess the level of B2M and CD49d in serum CLL patients and correlates them with treatment response. PATIENTS AND METHODS: this is a prospective cohort study conducted on 70 patients with CLL and 40 healthy people as a control group. Patient groups were divided into two groups: The first group included 38 patients before receiving treatment and the second group included 32 patients posttreatment. Diagnosis was based on lymphocyte count of >5 × 109/L and immunophenotyping. The measurement of level B2M and CD49d in serum patients was done using enzyme-linked immunosorbent assay. RESULTS: there were 53 males and 17 females, the mean age was 59.12 ± 14.23, and the most clinical presentation was lymphadenopathy. Regarding the mean of B2M, it was 2.19 ± 0.86, 1.86 ± 0.58, and 1.41 ± 0.44 in the pre, post, and control groups, respectively, with P = 0.0001. Regarding the mean of CD49d, it was 0.22 ± 0.15, 0.30 ± 0.44, and 0.19 ± 0.13 in the pre, post, and control groups, respectively, with P = 0.211. CONCLUSION: this study showed that CD49d has no clinical impact on the treatment outcome, yet B2M has an important prognostic factor in deciding patients in advance stage.http://www.ijhonline.org/article.asp?issn=2072-8069;year=2020;volume=9;issue=2;spage=155;epage=159;aulast=Al-Rekabibeta-2 microglobulincd49dchronic lymphocytic leukemia |
| spellingShingle | Abdulameer Nasser Al-Rekabi Alaa Fadhil Alwan Naseer Khaleel Alobaidi Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy Iraqi Journal of Hematology beta-2 microglobulin cd49d chronic lymphocytic leukemia |
| title | Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy |
| title_full | Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy |
| title_fullStr | Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy |
| title_full_unstemmed | Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy |
| title_short | Assessment of beta-2 microglobulin and CD49d in patients with chronic lymphocytic leukemia pre- and posttherapy |
| title_sort | assessment of beta 2 microglobulin and cd49d in patients with chronic lymphocytic leukemia pre and posttherapy |
| topic | beta-2 microglobulin cd49d chronic lymphocytic leukemia |
| url | http://www.ijhonline.org/article.asp?issn=2072-8069;year=2020;volume=9;issue=2;spage=155;epage=159;aulast=Al-Rekabi |
| work_keys_str_mv | AT abdulameernasseralrekabi assessmentofbeta2microglobulinandcd49dinpatientswithchroniclymphocyticleukemiapreandposttherapy AT alaafadhilalwan assessmentofbeta2microglobulinandcd49dinpatientswithchroniclymphocyticleukemiapreandposttherapy AT naseerkhaleelalobaidi assessmentofbeta2microglobulinandcd49dinpatientswithchroniclymphocyticleukemiapreandposttherapy |